U.S. regulators approved a new Merck & Co. vaccine that is designed to offer broader protection than existing vaccines against cervical cancer and other cancers caused by a sexually transmitted virus.. Gardasil 9, which Merck code-named V503 during development, targets five additional strains of the human papillomavirus, or HPV, not targeted by the original Gardasil, which Merck began selling in 2006. The wider set of HPV types targeted by the new Gardasil vaccine is believed to account for nearly 90% of all cases of cervical...
  